Skip to content
DataLookout
Menu

NCT03441113

Extended Access of Momelotinib in Adults With Myelofibrosis

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 57 versions: 46 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 4 more changesShow less
    • Eligibility criteria expanded, about 207 words
    • Study completion pushed from Dec 11, 2026 to Dec 29, 2028
    • Interventions modified
    • Site details revised at 31 of 112 sites
  2. Minor Study sites: 224 to 112
    • Primary and study completion dates: Dec 31, 2026 to Dec 11, 2026
    v55
  3. Notable Lead sponsor: Sierra Oncology LLC - a GSK company to GlaxoSmithKline
    • Enrollment target: estimated 400 to confirmed 237
    • Study sites: 113 to 224
    • Primary and study completion dates: Dec 2026 to Dec 31, 2026
    v53
  4. Minor Trial status: Enrolling by Invitation to Active, Not Recruitingv52
  5. Minor Study sites: 112 to 113v51
Show 41 earlier versionsHide 41 earlier versions
  1. Minor Study sites: 111 to 112v50
  2. Minor Study sites: 110 to 111v49
  3. Minor Study sites: 108 to 110v48
  4. Minor Study sites: 107 to 108v47
  5. Minor Study sites: 104 to 107v46
  6. Minor Study sites: 102 to 104v45
  7. Minor Study sites: 101 to 102v44
  8. Minor Study sites: 100 to 101v43
  9. Minor Study sites: 98 to 100v42
  10. Minor Study sites: 97 to 98v41
  11. Minor Study sites: 96 to 97v39
  12. Minor Study sites: 95 to 96v38
  13. Minor Study sites: 92 to 95v37
  14. Minor Study sites: 90 to 92v36
  15. Minor Study sites: 89 to 90v35
  16. Minor Study sites: 88 to 89v34
  17. Minor Study sites: 87 to 88v33
  18. Minor Study sites: 85 to 87v32
  19. Minor Study sites: 81 to 85v31
  20. Notable Primary and study completion dates: Dec 2024 to Dec 2026
    • Study sites: 79 to 81
    v30
  21. Minor Study sites: 78 to 79v29
  22. Minor Study sites: 77 to 78v28
  23. Minor Study sites: 76 to 77v27
  24. Minor Study sites: 75 to 76v26
  25. Minor Study sites: 73 to 75v25
  26. Minor Study sites: 71 to 73v24
  27. Minor Study sites: 70 to 71v23
  28. Minor Study sites: 69 to 70v22
  29. Minor Study sites: 67 to 69v21
  30. Notable Primary and study completion dates: Jun 2020 to Dec 2024v19
  31. Notable Enrollment target: 200 to 400
    • Study arms: 3 to 4
    v18
  32. Minor Study sites: 63 to 67v17
  33. Minor Study sites: 62 to 63v16
  34. Minor Study sites: 49 to 62v15
  35. Notable Lead sponsor: Gilead Sciences to Sierra Oncology LLC - a GSK companyv14
  36. Minor Study sites: 37 to 49v13
  37. Minor Study sites: 30 to 37v12
  38. Minor Study sites: 22 to 30v11
  39. Minor Study sites: 15 to 22v10
  40. Minor Study sites: 9 to 15v9
  41. Minor Study sites: 4 to 9v8
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) by severity
Timeframe: From study start until each participant transitions to PACT (up to approximately 556 weeks)

Secondary (2)

Overall survival (OS)
Leukemia free survival (LFS)

Arms and interventions

Cohort 1: Study GS-US-352-0101Other

Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-0101 until MMB receives regulatory approval and is commercially available, or development of the product ceases.

Cohort 2: Study GS-US-352-1214Other

Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1214 until MMB receives regulatory approval and is commercially available, or development of the product ceases.

Cohort 3: Study GS-US-352-1154Other

Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1154 until MMB receives regulatory approval and is commercially available, or development of the product ceases.

Cohort 4: Study SRA-MMB-301Other

Participants will continue to receive the same dosage regimen as in the previous MMB study SRA-MMB-301 until MMB receives regulatory approval and is commercially available, or development of the product ceases.

Drugs: Momelotinib

Sites

112 sites in 20 countries

United States 14, Italy 12, Spain 8, France 7, Germany 7, Hungary 7, Poland 7, Australia 6, Romania 6, South Korea 6, Israel 5, United Kingdom 5, Belgium 4, Bulgaria 4, Taiwan 4, Canada 3, Austria 2, Denmark 2, Singapore 2, Netherlands 1